Ascendis Pharma (ASND) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: EUR 247 million, which includes EUR 197 million from YORVIPATH and EUR 44 million from SKYTROFA, alongside EUR 6 million in collaboration revenue.

Operating Profit: EUR 25 million (10% operating margin), with non-IFRS operating profit at EUR 55 million (22% non-IFRS operating margin).

Net Profit: EUR 629 million, boosted by a EUR 679 million deferred tax asset recognition. Non-IFRS net profit was EUR 18 million (EUR 0.27 per share).

Cash Position: EUR 573 million in cash and cash equivalents, following a EUR 60 million impact from a share repurchase program.

R&D Expenses: EUR 59 million, down from EUR 78 million in Q4 2025, aided by a write-up of YUVIWEL inventory.

SG&A Expenses: Increased to EUR 145 million from EUR 136 million in Q4 2025 due to global commercial expansion efforts.

2Strategic Updates and Business Highlights

Product Approvals: FDA approval of YUVIWEL marks the third product launch in a row for Ascendis, expanding their portfolio in rare endocrine indications.

Pipeline Development: Over 20 ongoing or planned clinical trials, including 4 new clinical entities in preclinical development.

YORVIPATH Performance: Continued strong uptake with over 1,000 new patients prescribed in Q1 and a total of over 6,300 patients on therapy.

Market Expansion: YORVIPATH is available in 35 countries, with full commercial reimbursement in 6 European markets.

New Product Launches: YUVIWEL launched in early April, with over 60 prescriptions in the first few weeks, indicating strong demand.

3Forward Guidance and Outlook

YORVIPATH: Anticipated steady revenue growth in Q2, with expectations to reverse onetime impacts seen in Q1.

SKYTROFA: Expected stable revenue throughout the year, following a similar seasonal pattern to 2025.

YUVIWEL: Positive early demand trends noted, with further updates expected in Q2.

Operating Cash Flow Target: Reaffirmed target of EUR 500 million, with expectations for improved operating margins as revenue scales.

4Bad News, Challenges, or Points of Concern

Onetime Impacts: Q1 revenue was affected by a temporary increase in patients on free drug due to reimbursement disruptions and a one-time impact from Europe Direct.

Competitive Landscape: Concerns regarding potential competition from other treatments in the hypoparathyroidism space, particularly related to a recent Phase III trial by AstraZeneca.

Reimbursement Challenges: Ongoing complexities in the reimbursement process for YORVIPATH, although improvements in approval rates and timelines were noted.

5Notable Q&A Insights

YORVIPATH Sales Breakdown: Analysts sought clarity on U.S. versus ex-U.S. sales, with management indicating that the onetime impacts were primarily localized.

Reauthorization Rates: Reauthorization rates for YORVIPATH were reported to be consistent with initial patient approvals, indicating a stable demand.

Patient Demographics: YUVIWEL's initial uptake includes a mix of treatment-naive patients and switches from existing therapies, with ongoing efforts to support patient transitions.

Retention Rates: High retention rates in clinical trials were highlighted, showcasing patient satisfaction with treatment.

Capital Allocation Strategy: Focus on R&D investment to sustain long-term growth, with updates expected post-Q2 regarding financial outlook and strategic initiatives. This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Ascendis Pharma's Q1 2026 performance and outlook.